💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

U.S. environment agency says glyphosate weed killer is not a carcinogen

Published 05/01/2019, 05:02 AM
© Reuters. FILE PHOTO: A woman uses a Monsanto's Roundup weedkiller spray without glyphosate in a garden in Ercuis near Paris
BAYGN
-
MON
-

By Tom Polansek

CHICAGO (Reuters) - The U.S. Environmental Protection Agency (EPA) said on Tuesday that glyphosate, a chemical in many popular weed killers, is not a carcinogen, contradicting decisions by U.S. juries that found it caused cancer in people.

The EPA's announcement reaffirms its earlier findings about the safety of glyphosate, the key ingredient in Bayer's Roundup. The company faces thousands of lawsuits from Roundup users who allege it caused their cancer.

"EPA continues to find that there are no risks to public health when glyphosate is used in accordance with its current label and that glyphosate is not a carcinogen," the agency said in a statement.

Farmers spray glyphosate, the most widely used herbicide in U.S. agriculture, on fields of soybeans and other crops. Roundup is also used on lawns, golf courses and elsewhere.

The EPA did previously find ecological risks from the chemical and has proposed new measures to protect the environment from glyphosate use by farmers and to reduce the problem of weeds becoming resistant to it.

Bayer (DE:BAYGN) said it was pleased the EPA and other regulators who have assessed the science on glyphosate for more than 40 years continue to conclude it is not carcinogenic. "Bayer firmly believes that the science supports the safety of glyphosate-based herbicides," it said in a statement. The company has repeatedly denied allegations that glyphosate and Roundup cause cancer.

But critics of the chemical disputed the EPA's assurances.

"Unfortunately American consumers cannot trust the EPA assessment of glyphosate's safety," said Nathan Donley, a senior scientist at the environmental group Center for Biological Diversity.

Monsanto (NYSE:MON) developed Roundup as the first glyphosate-based weed killer, but it is no longer patent-protected and many other versions are available. Bayer bought Monsanto last year for $63 billion.

The debate over glyphosate's safety has put a spotlight on regulatory agencies around the world in recent years and, more recently, on U.S. courtrooms.

In 2015, the World Health Organization's cancer arm classified glyphosate as "probably carcinogenic to humans." But the EPA in 2017 said a decades-long assessment of glyphosate risks found the chemical was not likely carcinogenic to humans.

In February, analysts at Brazilian health agency Anvisa also determined the weed killer does not cause cancer while recommending limits on exposure.

In the first U.S. Roundup trial, a California man was awarded $289 million in August 2018 after a state court jury found the weed killer caused his cancer. That award was later reduced to $78 million and is being appealed by Bayer.

© Reuters. FILE PHOTO: A woman uses a Monsanto's Roundup weedkiller spray without glyphosate in a garden in Ercuis near Paris

A U.S. jury in March awarded $80 million to another California man who claimed his use of Roundup caused his cancer.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.